Gender specific aspects of cell death in the cardiovascular system

Current Pharmaceutical Design

Volumn 17, Issue 11, 2011, Pages 1046-1055

  Pierdominici, Marina ^a   Ortona, Elena ^a   Franconi, Flavia ^b   Caprio, Massimiliano ^c   Straface, Elisabetta ^a   Malorni, Walter ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c Scientific Institute   (Italy)

Author keywords

Apoptosis; Cardiomyocytes; Cardiovascular; Cell death; Endothelial cells; Gender; Sex hormones; Vascular smooth muscle cells

Indexed keywords

ANDROGEN RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; SEX HORMONE; TESTOSTERONE;

APOPTOSIS; ATHEROSCLEROSIS; AUTOPHAGY; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL DAMAGE; CELL DEATH; CELL FATE; CELL FUNCTION; DISEASE COURSE; ENDOTHELIUM CELL; HEART; HEART FAILURE; HEART MUSCLE CELL; HOMEOSTASIS; HUMAN; MOLECULAR INTERACTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SMOOTH MUSCLE FIBER;

EID: 79958184429     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795656891     Document Type: Review

References (156)

1. Jolly K, Gill P. Ethnicity and cardiovascular disease prevention:Practical clinical considerations. Curr Opin Cardiol 2008; 23: 465-70.
2. Mercuro G, Deidda M, Piras A, Dessalvi CC, Maffei S, Rosano GM. Gender determinants of cardiovascular risk factors and diseases. J Cardiovasc Med 2010; 11: 207-20.
3. Pilote L, Dasgupta K, Guru V, et al. A comprehensive view of sexspecificissues related to cardiovascular disease. CMAJ 2007; 176:S1-44.
4. Vitale C, Miceli M, Rosano GM. Gender-specific characteristics ofatherosclerosis in menopausal women: Risk factors, clinical courseand strategies for prevention. Climacteric 2007; 10 Suppl 2: 16-20.
5. Ascenzi P, Bocedi A, Marino M. Structure-function relationship ofestrogen receptor alpha and beta: Impact on human health. MolAspects Med 2006; 27: 299-402.
6. Deroo BJ, Korach KS. Estrogen receptors and human disease. JClin Invest 2006; 116: 561-70.
7. Clarke M, Bennett M, Littlewood T. Cell death in the cardiovascularsystem. Heart 2007; 93: 659-64.
8. Grazette LP, Rosenzweig A. Role of apoptosis in heart failure. Heart Fail Clin 2005; 1: 251-61.
9. Lee Y, Gustafsson AB. Role of apoptosis in cardiovascular disease. Apoptosis 2009; 14: 536-48.
10. Degterev A, Yuan J. Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 2008; 9: 378-90.
11. Stoneman VE, Bennett MR. Role of fas/fas-l in vascular cell apoptosis. J Cardiovasc Pharmacol 2009; 53: 100-8.
12. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumournecrosis factor alpha in severe congestive cardiac failure. Br HeartJ 1993; 70: 141-3.
13. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulatinglevels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-41.
14. Pober JS, Min W, Bradley JR. Mechanisms of endothelial dysfunction,injury, and death. Annu Rev Pathol 2009; 4: 71-95.
15. Logue SE, Gustafsson AB, Samali A, Gottlieb RA. Ischemia/reperfusion injury at the intersection with cell death. J MolCell Cardiol 2005; 38: 21-33.
16. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J.Free radicals and antioxidants in normal physiological functionsand human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
17. Kukreja RC, Hess ML. The oxygen free radical system: Fromequations through membrane-protein interactions to cardiovascularinjury and protection. Cardiovasc Res 1992; 26: 641-55.
18. Lopez-Candales A, Holmes DR, Liao S, Scott MJ, Wickline SA,Thompson RW. Decreased vascular smooth muscle cell density inmedial degeneration of human abdominal aortic aneurysms. Am JPathol 1997; 150: 993-1007.
19. Winn RK, Harlan JM. The role of endothelial cell apoptosis ininflammatory and immune diseases. J Thromb Haemost 2005; 3:1815-24.
20. Mallat Z, Tedgui A. Apoptosis in the vasculature: Mechanisms andfunctional importance. Br J Pharmacol 2000; 130: 947-62.
21. Reggiori F, Klionsky DJ. Autophagosomes: Biogenesis fromscratch? Curr Opin Cell Biol 2005; 17: 415-22.
22. Tinari A, Matarrese P, Minetti M, Malorni W. Hyperphagia by selfandxeno-cannibalism: Cell death by indigestion?: A reminiscenceof the phedrus fabula Rana rupta et bos? Autophagy 2008; 4:128-30.
23. Kitsis RN, Peng CF, Cuervo AM. Eat your heart out. Nat Med 2007; 13: 539-41.
24. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation usingtransgenic mice expressing a fluorescent autophagosomemarker. Mol Biol Cell 2004; 15: 1101-11.
25. Sybers HD, Ingwall J, DeLuca M. Autophagy in cardiac myocytes. Recent Adv Stud Cardiac Struct Metab 1976; 12: 453-63.
26. Decker RS, Wildenthal K. Lysosomal alterations in hypoxic andreoxygenated hearts. I. Ultrastructural and cytochemical changes. Am J Pathol 1980; 98: 425-44.
27. Yan L, Vatner DE, Kim SJ, et al. Autophagy in chronicallyischemic myocardium. Proc Natl Acad Sci USA 2005; 102: 13807-12.
28. Hamacher-Brady A, Brady NR, Gottlieb RA. Enhancing macroautophagyprotects against ischemia/reperfusion injury in cardiacmyocytes. J Biol Chem 2006; 281: 29776-87.
29. Nakai A, Yamaguchi O, Takeda T, et al. The role of autophagy incardiomyocytes in the basal state and in response to hemodynamicstress. Nat Med 2007; 13: 619-24.
30. Martinet W, Knaapen MW, Kockx MM, De Meyer GR. Autophagyin cardiovascular disease. Trends Mol Med 2007; 13: 482-91.
31. Valentim L, Laurence KM, Townsend PA, et al. Urocortin inhibitsbeclin1-mediated autophagic cell death in cardiac myocytes exposedto ischaemia/reperfusion injury. J Mol Cell Cardiol 2006; 40:846-52.
32. Matsui Y, Takagi H, Qu X, et al. Distinct roles of autophagy in theheart during ischemia and reperfusion: Roles of amp-activated proteinkinase and beclin 1 in mediating autophagy. Circ Res 2007;100: 914-22.
33. De Meyer GR, Martinet W. Autophagy in the cardiovascular system. Biochim Biophys Acta 2009; 1793: 1485-95.
34. Kiffin R, Bandyopadhyay U, Cuervo AM. Oxidative stress andautophagy. Antioxid Redox Signal 2006; 8: 152-62.
35. Levine B, Yuan J. Autophagy in cell death: An innocent convict? JClin Invest 2005; 115: 2679-88.
36. Hsieh YC, Athar M, Chaudry IH. When apoptosis meets autophagy:Deciding cell fate after trauma and sepsis. Trends Mol Med 2009; 15: 129-38.
37. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagyfights disease through cellular self-digestion. Nature 2008; 451:1069-75.
38. Nishida K, Yamaguchi O, Otsu K. Crosstalk between autophagyand apoptosis in heart disease. Circ Res 2008; 103: 343-51.
39. Kim I, Rodriguez-Enriquez S, Lemasters JJ. Selective degradationof mitochondria by mitophagy. Arch Biochem Biophys 2007; 462:245-53.
40. Searle J, Kerr JF, Bishop CJ. Necrosis and apoptosis: Distinctmodes of cell death with fundamentally different significance. Pathol Annu 1982; 17 Pt 2: 229-59.
41. Vanlangenakker N, Vanden Berghe T, Krysko DV, Festjens N, Vandenabeele P. Molecular mechanisms and pathophysiology ofnecrotic cell death. Curr Mol Med 2008; 8: 207-20.
42. Tavernarakis N. Cardiomyocyte necrosis: Alternative mechanisms,effective interventions. Biochim Biophys Acta 2007; 1773: 480-2.
43. Casey TM, Arthur PG, Bogoyevitch MA. Necrotic death withoutmitochondrial dysfunction-delayed death of cardiac myocytes followingoxidative stress. Biochim Biophys Acta 2007; 1773: 342-51.
44. Vitale C, Mendelsohn ME, Rosano GM. Gender differences in thecardiovascular effect of sex hormones. Nat Rev Cardiol 2009; 6:532-42.
45. Ellis JA, Stebbing M, Harrap SB. Association of the human ychromosome with high blood pressure in the general population. Hypertension 2000; 36: 731-3.
46. Charchar FJ, Tomaszewski M, Lacka B, et al. Association of thehuman y chromosome with cholesterol levels in the general population. Arterioscler Thromb Vasc Biol 2004; 24: 308-12.
47. Jin JJ, Nakura J, Wu Z, et al. Association of angiotensin ii type 2receptor gene variant with hypertension. Hypertens Res 2003; 26:547-52.
48. Ortona E, Margutti P, Matarrese P, Franconi F, Malorni W. Redoxstate, cell death and autoimmune diseases: A gender perspective. Autoimmun Rev 2008; 7: 579-84.
49. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoidarthritis and systemic lupus erythematosus. Am J Med 2008; 121:S3-8.
50. Praprotnik S, Blank M, Levy Y, et al. Anti-endothelial cell antibodiesfrom patients with thrombotic thrombocytopenic purpura specificallyactivate small vessel endothelial cells. Int Immunol 2001;13: 203-10.
51. Margutti P, Delunardo F, Colasanti T, et al. Screening of endothelialexpression libraries for the identification of novel autoantigensinvolved in distinct autoimmune diseases characterized by endothelialdysfunction. Ann N Y Acad Sci 2007; 1109: 178-84.
52. Tobon GJ, Alard JE, Youinou P, Jamin C. Are autoantibodies triggeringendothelial cell apoptosis really pathogenic? AutoimmunRev 2009; 8: 605-10.
53. Margutti P, Matarrese P, Conti F, et al. Autoantibodies to the cterminalsubunit of rlip76 induce oxidative stress and endothelialcell apoptosis in immune-mediated vascular diseases and atherosclerosis. Blood 2008; 111: 4559-70.
54. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovasculargender differences. Science 2005; 308: 1583-7.
55. McKenna NJ, O'Malley BW. Combinatorial control of gene expressionby nuclear receptors and coregulators. Cell 2002; 108:465-74.
56. Smith CL, O'Malley BW. Coregulator function: A key to understandingtissue specificity of selective receptor modulators. EndocrRev 2004; 25: 45-71.
57. Maselli A, Matarrese P, Straface E, Canu S, Franconi F, MalorniW. Cell sex: A new look at cell fate studies. FASEB J 2009; 23:978-84.
58. Edwards DP. Regulation of signal transduction pathways by estrogenand progesterone. Annu Rev Physiol 2005; 67: 335-76.
59. Ihionkhan CE, Chambliss KL, Gibson LL, Hahner LD, MendelsohnME, Shaul PW. Estrogen causes dynamic alterations in endothelialestrogen receptor expression. Circ Res 2002; 91: 814-20.
60. Shearman AM, Cupples LA, Demissie S, et al. Association betweenestrogen receptor alpha gene variation and cardiovasculardisease. JAMA 2003; 290: 2263-70.
61. Herrington DM. Role of estrogen receptor-alpha in pharmacogeneticsof estrogen action. Curr Opin Lipidol 2003; 14: 145-50.
62. Miller VM, Duckles SP. Vascular actions of estrogens: Functionalimplications. Pharmacol Rev 2008; 60: 210-41.
63. Mendelsohn ME, Karas RH. The protective effects of estrogen onthe cardiovascular system. N Engl J Med 1999; 340: 1801-11.
64. Ling S, Komesaroff P, Sudhir K. Cellular mechanisms underlyingthe cardiovascular actions of oestrogens. Clin Sci (Lond) 2006;111: 107-18.
65. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogenaction. Physiol Rev 2001; 81: 1535-65.
66. O'Lone R, Frith MC, Karlsson EK, Hansen U. Genomic targets ofnuclear estrogen receptors. Mol Endocrinol 2004; 18: 1859-75.
67. Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptorengagement activates endothelial nitric oxide synthase via thepi3-kinase-akt pathway in human endothelial cells. Circ Res 2000;87: 677-82.
68. Moriarty K, Kim KH, Bender JR. Minireview: Estrogen receptormediatedrapid signaling. Endocrinology 2006; 147: 5557-63.
69. Levin ER. Plasma membrane estrogen receptors. Trends EndocrinolMetab 2009; 20: 479-82.
70. Marino M, Ascenzi P, Acconcia F. S-palmitoylation modulatesestrogen receptor alpha localization and functions. Steroids 2006;71: 298-303.
71. Levin ER. Integration of the extranuclear and nuclear actions ofestrogen. Mol Endocrinol 2005; 19: 1951-9.
72. Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiplepathways to impact gene transcription. Curr Genomics 2006; 7:497-508.
73. Haynes MP, Li L, Russell KS, Bender JR. Rapid vascular cellresponses to estrogen and membrane receptors. Vascul Pharmacol 2002; 38: 99-108.
74. Chen JQ, Cammarata PR, Baines CP, Yager JD. Regulation ofmitochondrial respiratory chain biogenesis by estrogens/estrogenreceptors and physiological, pathological and pharmacological implications. Biochim Biophys Acta 2009; 1793: 1540-70.
75. Mendelsohn ME. Mechanisms of estrogen action in the cardiovascularsystem. J Steroid Biochem Mol Biol 2000; 74: 337-43.
76. Jankowski M, Rachelska G, Donghao W, McCann SM, GutkowskaJ. Estrogen receptors activate atrial natriuretic peptide in the ratheart. Proc Natl Acad Sci USA 2001; 98: 11765-70.
77. Saunders PT, Maguire SM, Gaughan J, Millar MR. Expression ofoestrogen receptor beta (er beta) in multiple rat tissues visualisedby immunohistochemistry. J Endocrinol 1997; 154: R13-6.
78. Savolainen H, Frosen J, Petrov L, Aavik E, Hayry P. Expression ofestrogen receptor sub-types alpha and beta in acute and chroniccardiac allograft vasculopathy. J Heart Lung Transplant 2001; 20:1252-64.
79. Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptorbeta in human tissues. J Mol Endocrinol 2000; 24: 145-55.
80. Xu Y, Arenas IA, Armstrong SJ, Davidge ST. Estrogen modulationof left ventricular remodeling in the aged heart. Cardiovasc Res 2003; 57: 388-94.
81. Yang SH, Liu R, Perez EJ, et al. Mitochondrial localization ofestrogen receptor beta. Proc Natl Acad Sci USA 2004; 101: 4130-5.
82. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovasculardisease. Endocr Rev 2003; 24: 313-40.
83. Death AK, McGrath KC, Sader MA, et al. Dihydrotestosteronepromotes vascular cell adhesion molecule-1 expression in malehuman endothelial cells via a nuclear factor-kappab-dependentpathway. Endocrinology 2004; 145: 1889-97.
84. McCrohon JA, Death AK, Nakhla S, et al. Androgen receptorexpression is greater in macrophages from male than from femaledonors. A sex difference with implications for atherogenesis. Circulation 2000; 101: 224-6.
85. Sader MA, McGrath KC, Hill MD, et al. Androgen receptor geneexpression in leucocytes is hormonally regulated: Implications forgender differences in disease pathogenesis. Clin Endocrinol (Oxf) 2005; 62: 56-63.
86. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, WilsonEM, French FS. Androgen receptor defects: Historical, clinical, andmolecular perspectives. Endocr Rev 1995; 16: 271-321.
87. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: Anoverview. Endocr Rev 2002; 23: 175-200.
88. Gregory CW, He B, Wilson EM. The putative androgen receptor-Aform results from in vitro proteolysis. J Mol Endocrinol 2001; 27:309-19.
89. Heinlein CA, Chang C. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 2002; 16: 2181-7.
90. Halvorsen B, Otterdal K, Dahl TB, et al. Atherosclerotic plaquestability--what determines the fate of a plaque? Prog CardiovascDis 2008; 51: 183-94.
91. Martinet W, De Meyer GR. Autophagy in atherosclerosis. CurrAtheroscler Rep 2008; 10: 216-23.
92. Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of17beta-estradiol on cytokine-induced endothelial cell adhesionmolecule expression. J Clin Invest 1996; 98: 36-42.
93. Haynes MP, Li L, Sinha D, et al. Src kinase mediates phosphatidylinositol3-kinase/akt-dependent rapid endothelial nitric-oxide synthaseactivation by estrogen. J Biol Chem 2003; 278: 2118-23.
94. Li L, Haynes MP, Bender JR. Plasma membrane localization andfunction of the estrogen receptor alpha variant (ER46) in humanendothelial cells. Proc Natl Acad Sci USA 2003; 100: 4807-12.
95. Williams JK, Adams MR, Herrington DM, Clarkson TB. Shorttermadministration of estrogen and vascular responses of atheroscleroticcoronary arteries. J Am Coll Cardiol 1992; 20: 452-7.
96. Stirone C, Boroujerdi A, Duckles SP, Krause DN. Estrogen receptoractivation of phosphoinositide-3 kinase, akt, and nitric oxidesignaling in cerebral blood vessels: Rapid and long-term effects. Mol Pharmacol 2005; 67: 105-13.
97. Li L, Hisamoto K, Kim KH, et al. Variant estrogen receptor-c-srcmolecular interdependence and c-src structural requirements forendothelial no synthase activation. Proc Natl Acad Sci USA 2007;104: 16468-73.
98. Stirone C, Duckles SP, Krause DN, Procaccio V. Estrogen increasesmitochondrial efficiency and reduces oxidative stress incerebral blood vessels. Mol Pharmacol 2005; 68: 959-65.
99. Duckles SP, Krause DN, Stirone C, Procaccio V. Estrogen andmitochondria: A new paradigm for vascular protection? Mol Interv 2006; 6: 26-35.
100. St-Pierre J, Drori S, Uldry M, et al. Suppression of reactive oxygenspecies and neurodegeneration by the pgc-1 transcriptional coactivators. Cell 2006; 127: 397-408.
101. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascularendothelial cells become procoagulant. Blood 1997; 89: 2429-42.
102. Spyridopoulos I, Sullivan AB, Kearney M, Isner JM, Losordo DW.Estrogen-receptor-mediated inhibition of human endothelial cellapoptosis. Estradiol as a survival factor. Circulation 1997; 95:1505-14.
103. Florian M, Florianova L, Hussain S, Magder S. Interaction of estrogenand tumor necrosis factor alpha in endothelial cell migrationand early stage of angiogenesis. Endothelium 2008; 15: 265-75.
104. Lu A, Frink M, Choudhry MA, et al. Mitochondria play an importantrole in 17beta-estradiol attenuation of h(2)o(2)-induced rat endothelialcell apoptosis. Am J Physiol Endocrinol Metab 2007; 292:E585-93.
105. Ling S, Zhou L, Li H, et al. Effects of 17beta-estradiol on growthand apoptosis in human vascular endothelial cells: Influence of mechanicalstrain and tumor necrosis factor-alpha. Steroids 2006; 71:799-808.
106. Alvarez RJ, Gips SJ, Moldovan N, et al. 17beta-estradiol inhibitsapoptosis of endothelial cells. Biochem Biophys Res Commun 1997; 237: 372-81.
107. Seli E, Guzeloglu-Kayisli O, Cakmak H, Kayisli UA, Selam B, Arici A. Estradiol increases apoptosis in human coronary artery endothelialcells by up-regulating fas and fas ligand expression. J ClinEndocrinol Metab 2006; 91: 4995-5001.
108. Ling S, Dai A, Williams MR, et al. Testosterone (t) enhances apoptosis-related damage in human vascular endothelial cells. Endocrinology 2002; 143: 1119-25.
109. Clarke MC, Figg N, Maguire JJ, et al. Apoptosis of vascularsmooth muscle cells induces features of plaque vulnerability inatherosclerosis. Nat Med 2006; 12: 1075-80.
110. Jia G, Cheng G, Agrawal DK. Autophagy of vascular smooth musclecells in atherosclerotic lesions. Autophagy 2007; 3: 63-4.
111. Malorni W, Straface E, Matarrese P, et al. Redox state and genderdifferences in vascular smooth muscle cells. FEBS Lett 2008; 582:635-42.
112. Straface E, Vona R, Gambardella L, et al. Cell sex determinesanoikis resistance in vascular smooth muscle cells. FEBS Lett 2009; 583: 3448-54.
113. Mori-Abe A, Tsutsumi S, Takahashi K, et al. Estrogen andraloxifene induce apoptosis by activating p38 mitogen-activatedprotein kinase cascade in synthetic vascular smooth muscle cells. JEndocrinol 2003; 178: 417-26.
114. Yang Z, Cheng B, Song J, Wan Y, Wang Q, Chen X. Estrogenaccelerates g1 to s phase transition and induces a g2/m phasepredominantapoptosis in synthetic vascular smooth muscle cells. Int J Cardiol 2007; 118: 381-8.
115. Bowles DK, Maddali KK, Dhulipala VC, Korzick DH. Pkcdeltamediates anti-proliferative, pro-apoptic effects of testosterone oncoronary smooth muscle. Am J Physiol Cell Physiol 2007; 293:C805-13.
116. Beltrami CA, Finato N, Rocco M, et al. Structural basis of endstagefailure in ischemic cardiomyopathy in humans. Circulation 1994; 89: 151-63.
117. Beltrami CA, Finato N, Rocco M, et al. The cellular basis of dilatedcardiomyopathy in humans. J Mol Cell Cardiol 1995; 27:291-305.
118. Olivetti G, Melissari M, Balbi T, et al. Myocyte cellular hypertrophyis responsible for ventricular remodelling in the hypertrophiedheart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res 1994; 28: 1199-208.
119. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes inend-stage heart failure. N Engl J Med 1996; 335: 1182-9.
120. Narula J, Pandey P, Arbustini E, et al. Apoptosis in heart failure:Release of cytochrome c from mitochondria and activation ofcaspase-3 in human cardiomyopathy. Proc Natl Acad Sci USA 1999; 96: 8144-9.
121. Olivetti G, Quaini F, Sala R, et al. Acute myocardial infarction inhumans is associated with activation of programmed myocyte celldeath in the surviving portion of the heart. J Mol Cell Cardiol 1996;28: 2005-16.
122. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM. Apoptosis in human acute myocardial infarction. Circulation 1997; 95: 320-3.
123. Saraste A, Pulkki K, Kallajoki M, et al. Cardiomyocyte apoptosisand progression of heart failure to transplantation. Eur J Clin Invest 1999; 29: 380-6.
124. Aharinejad S, Andrukhova O, Lucas T, et al. Programmed celldeath in idiopathic dilated cardiomyopathy is mediated by suppressionof the apoptosis inhibitor apollon. Ann Thorac Surg 2008; 86:109-14 discussion 14.
125. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL.Reperfusion injury induces apoptosis in rabbit cardiomyocytes. JClin Invest 1994; 94: 1621-8.
126. Cheng W, Kajstura J, Nitahara JA, et al. Programmed myocyte celldeath affects the viable myocardium after infarction in rats. ExpCell Res 1996; 226: 316-27.
127. Gao HK, Yin Z, Zhou N, Feng XY, Gao F, Wang HC. Glycogensynthase kinase 3 inhibition protects the heart from acute ischemiareperfusioninjury via inhibition of inflammation and apoptosis. JCardiovasc Pharmacol 2008; 52: 286-92.
128. Olivetti G, Giordano G, Corradi D, et al. Gender differences andaging: Effects on the human heart. J Am Coll Cardiol 1995; 26:1068-79.
129. Mallat Z, Fornes P, Costagliola R, et al. Age and gender effects oncardiomyocyte apoptosis in the normal human heart. J Gerontol ABiol Sci Med Sci 2001; 56: M719-23.
130. Guerra S, Leri A, Wang X, et al. Myocyte death in the failing humanheart is gender dependent. Circ Res 1999; 85: 856-66.
131. Pelzer T, Schumann M, Neumann M, et al. 17beta-estradiol preventsprogrammed cell death in cardiac myocytes. Biochem BiophysRes Commun 2000; 268: 192-200.
132. Kandel ES, Hay N. The regulation and activities of the multifunctionalserine/threonine kinase akt/pkb. Exp Cell Res 1999; 253:210-29.
133. Camper-Kirby D, Welch S, Walker A, et al. Myocardial akt activationand gender: Increased nuclear activity in females versus males. Circ Res 2001; 88: 1020-7.
134. Patten RD, Pourati I, Aronovitz MJ, et al. 17beta-estradiol reducescardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/akt signaling. Circ Res 2004; 95: 692-9.
135. Kim JK, Pedram A, Razandi M, Levin ER. Estrogen prevents cardiomyocyteapoptosis through inhibition of reactive oxygen speciesand differential regulation of p38 kinase isoforms. J Biol Chem 2006; 281: 6760-7.
136. Zhao ZQ. Oxidative stress-elicited myocardial apoptosis duringreperfusion. Curr Opin Pharmacol 2004; 4: 159-65.
137. See F, Thomas W, Way K, et al. P38 mitogen-activated proteinkinase inhibition improves cardiac function and attenuates left ventricularremodeling following myocardial infarction in the rat. J AmColl Cardiol 2004; 44: 1679-89.
138. Kaiser RA, Bueno OF, Lips DJ, et al. Targeted inhibition of p38mitogen-activated protein kinase antagonizes cardiac injury andcell death following ischemia-reperfusion in vivo. J Biol Chem 2004; 279: 15524-30.
139. Jiang Y, Chen C, Li Z, et al. Characterization of the structure andfunction of a new mitogen-activated protein kinase (p38beta). JBiol Chem 1996; 271: 17920-6.
140. Lemke LE, Bloem LJ, Fouts R, Esterman M, Sandusky G, Vlahos CJ. Decreased p38 mapk activity in end-stage failing human myocardium:P38 mapk alpha is the predominant isoform expressed inhuman heart. J Mol Cell Cardiol 2001; 33: 1527-40.
141. Saurin AT, Martin JL, Heads RJ, et al. The role of differentialactivation of p38-mitogen-activated protein kinase in preconditionedventricular myocytes. FASEB J 2000; 14: 2237-46.
142. Wang Y, Huang S, Sah VP, et al. Cardiac muscle cell hypertrophyand apoptosis induced by distinct members of the p38 mitogenactivatedprotein kinase family. J Biol Chem 1998; 273: 2161-8.
143. Krieg M, Smith K, Bartsch W. Demonstration of a specific androgenreceptor in rat heart muscle: Relationship between binding, metabolism,and tissue levels of androgens. Endocrinology 1978; 103:1686-94.
144. Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ. Androgen receptors mediate hypertrophy in cardiacmyocytes. Circulation 1998; 98: 256-61.
145. Wang M, Tsai BM, Kher A, Baker LB, Wairiuko GM, Meldrum DR. Role of endogenous testosterone in myocardial proinflammatoryand proapoptotic signaling after acute ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2005; 288: H221-6.
146. Kohno H, Takahashi N, Shinohara T, et al. Receptor-mediatedsuppression of cardiac heat-shock protein 72 expression by testosteronein male rat heart. Endocrinology 2007; 148: 3148-55.
147. Welder AA, Robertson JW, Fugate RD, Melchert RB. Anabolicandrogenicsteroid-induced toxicity in primary neonatal rat myocardialcell cultures. Toxicol Appl Pharmacol 1995; 133: 328-42.
148. Zaugg M, Jamali NZ, Lucchinetti E, et al. Anabolic-androgenicsteroids induce apoptotic cell death in adult rat ventricular myocytes. J Cell Physiol 2001; 187: 90-5.
149. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogenplus progestin for secondary prevention of coronary heart diseasein postmenopausal women. Heart and estrogen/progestin replacementstudy (hers) research group. JAMA 1998; 280: 605-13.
150. Grady D, Herrington D, Bittner V, et al. Cardiovascular diseaseoutcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (hers ii). JAMA 2002;288: 49-57.
151. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefitsof estrogen plus progestin in healthy postmenopausal women: Principalresults from the women's health initiative randomized controlledtrial. JAMA 2002; 288: 321-33.
152. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin andthe risk of coronary heart disease. N Engl J Med 2003; 349: 523-34.
153. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugatedequine estrogen in postmenopausal women with hysterectomy: Thewomen's health initiative randomized controlled trial. JAMA 2004;291: 1701-12.
154. Nishida K, Kyoi S, Yamaguchi O, Sadoshima J, Otsu K. The roleof autophagy in the heart. Cell Death Differ 2009; 16: 31-8.
155. Haeger P, Andres ME, Forray MI, Daza C, Araneda S, Gysling K.Estrogen receptors alpha and beta differentially regulate the transcriptionalactivity of the urocortin gene. J Neurosci 2006; 26:4908-16.
156. Florian M, Magder S. Estrogen decreases tnf-alpha and oxidized ldlinduced apoptosis in endothelial cells. Steroids 2008; 73: 47-58.